http://www.unboundmedicine.com/medline/ebm/research/sargramostimUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.http://www.unboundmedicine.com/medline/ebm/record/19707380/full_citation/New_treatment_options_in_the_management_of_IBD___focus_on_colony_stimulating_factors_Barahona-Garrido J, Yamamoto-Furusho JK 
New treatment options in the management of IBD - focus on colony stimulating factors. [Journal Article]
Biologics 2008 Sep; 2(3):501-4.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19637341/full_citation/Comparison_of_hospitalization_risk_and_associated_costs_among_patients_receiving_sargramostim_filgrastim_and_pegfilgrastim_for_chemotherapy_Induced_neutropenia_Heaney ML, Toy EL, Vekeman F, et al. 
Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-Induced neutropenia. [JOURNAL ARTICLE]
Cancer 2009 Jul 27.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19636911/full_citation/NMR_assignment_of_human_granulocyte_macrophage_colony_stimulating_factor_Sauvé S, Gingras G, Aubin Y 
NMR assignment of human granulocyte-macrophage colony-stimulating factor. [Journal Article]
Biomol NMR Assign 2008 Jun; 2(1):5-7.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19636017/full_citation/Safety_and_Immunological_Efficacy_of_a_DNA_Vaccine_Encoding_Prostatic_Acid_Phosphatase_in_Patients_With_Stage_D0_Prostate_Cancer_McNeel DG, Dunphy EJ, Davies JG, et al. 
Safety and Immunological Efficacy of a DNA Vaccine Encoding Prostatic Acid Phosphatase in Patients With Stage D0 Prostate Cancer. [JOURNAL ARTICLE]
J Clin Oncol 2009 Jul 27.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19635998/full_citation/Immunotherapy_for_Prostate_Cancer:_Walk_Don't_Run_Drake CG 
Immunotherapy for Prostate Cancer: Walk, Don't Run. [JOURNAL ARTICLE]
J Clin Oncol 2009 Jul 27.
Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19513041/full_citation/Genzyme_takes_Campath_bet_Huggett B 
Genzyme takes Campath bet. [News]
Nat Biotechnol 2009 Jun; 27(6):498.
Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19505878/full_citation/Steroid_sparing_Properties_of_Sargramostim_in_Patients_With_Corticosteroid_dependent_Crohn's_disease:_A_Randomised_Double_blind_Placebo_controlled_Phase_2_Study_Valentine JF, Fedorak RN, Feagan B, et al. 
Steroid-sparing Properties of Sargramostim in Patients With Corticosteroid-dependent Crohn's disease: A Randomised, Double-blind, Placebo-controlled, Phase 2 Study. [JOURNAL ARTICLE]
Gut 2009 Jun 7.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19483646/full_citation/Recombinant_Human_Granulocyte_macrophage_Colony_stimulating_Factor__GM_CSF_Sargramostim__Administered_for_3_Years_as_Adjuvant_Therapy_of_Stages_II_T4__III_and_IV_Melanoma_Spitler LE, Weber RW, Allen RE, et al. 
Recombinant Human Granulocyte-macrophage Colony-stimulating Factor (GM-CSF, Sargramostim) Administered for 3 Years as Adjuvant Therapy of Stages II(T4), III, and IV Melanoma. [JOURNAL ARTICLE]
J Immunother 2009 May 28.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19352588/full_citation/Sargramostim_in_patients_with_Crohn's_disease:_results_of_a_phase_1_2_study_Takazoe M, Matsui T, Motoya S, et al. 
Sargramostim in patients with Crohn's disease: results of a phase 1-2 study. [JOURNAL ARTICLE]
J Gastroenterol 2009 Apr 8.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19307996/full_citation/A_phase_1_study_of_granulocyte_macrophage_colony_stimulating_factor__sargramostim__and_escalating_doses_of_thalidomide_in_patients_with_high_risk_malignant_melanoma_Lutzky J, Weber R, Nunez Y, et al. 
A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma. [Journal Article, Research Support, Non-U.S. Gov't]
J Immunother 2009 Jan; 32(1):79-85.
Abstract | Full Citation